{
    "organizations": [],
    "uuid": "79b4d953c9bc292b83d9787b42ebd1d3540e572c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bellerophon-says-over-100-patients/brief-bellerophon-says-over-100-patients-in-late-stage-study-testing-inopulse-for-treatment-of-high-blood-pressure-idUSFWN1PO0XQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Bellerophon Says Over 100 Patients In Late-Stage Study Testing Inopulse For Treatment Of High Blood Pressure",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Bellerophon Therapeutics Inc:\n* BELLEROPHON THERAPEUTICS ANNOUNCES ENROLLMENT EXCEEDS 100 PATIENTS IN PHASE 3 INOVATION-1 STUDY EVALUATING INOPULSEÂ® FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION\n* BELLEROPHON - ANTICIPATES AVAILABILITY OF TOP-LINE DATA FROM PHASE 3 INOVATION-1 STUDY TOWARD END OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T21:36:00.000+02:00",
    "crawled": "2018-01-30T18:51:13.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "bellerophon",
        "therapeutic",
        "inc",
        "bellerophon",
        "therapeutic",
        "announces",
        "enrollment",
        "exceeds",
        "patient",
        "phase",
        "study",
        "evaluating",
        "treatment",
        "pulmonary",
        "arterial",
        "hypertension",
        "bellerophon",
        "anticipates",
        "availability",
        "data",
        "phase",
        "study",
        "toward",
        "end",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}